A. W. Armstrong, “Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”, J of Skin, vol. 7, no. 6, p. s240, Nov. 2023.